ÂÜÀòÂÒÂ×

Guy Goldberg is the Chief Business Officer at RedHill Biopharma. Prior to their current position, they served as a Senior Analyst for Planning & Analysis at Teva Pharmaceuticals from January 2005 to December 2012. In this role, they were responsible for business analysis and financial reporting activities, including forecasts, quarter close, and annual budget. Guy also coordinated financial reporting reconciliation between business units and corporate controllers, handling revenue and cost mismatches, proper booking of allocations, royalties, and unrealized profit. Additionally, they served as post-merger integration coordinator overseeing the PPA implementation and financial integration, including the financial planning, business analysis, and accounting activities.

Before joining Teva Pharmaceuticals, Guy Goldberg worked as a Transfer Pricing Associate at Ernst & Young from January 2003 to December 2005.

Guy Goldberg has a proven track record in financial planning and analysis, business analysis, and project management. Guy is an expert in Oracle Hyperion and has experience leading the annual capital expenditure budget review and project approval process.

Guy Goldberg pursued a Master’s Degree in Accounting at Baruch College. Prior to that, they completed a Bachelor of Business Administration (B.B.A.) in Economics & Finance at the same school.

They work with Clara Fehrmann - Director of Clinical Operations, June Almenoff - Chief Scientific Officer, and Valerie Graceffa - VP, US Sales. Guy Goldberg reports to Dror Ben-Asher, CEO.